NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

Die Nachricht ist zwar vom Januar 2019, aber sie hilft das Ausmaß des Nantworks Netzwerkes besser einzuordnen: NantCell Announces New Celgene Investment by Jen Hodson | Jan 4, 2019 | Press Releases Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding Brings Celgene’s Investment to $105M in NantCell Valued at $4 Billion Currently Enrolling Patients in Advanced Stage Trials in 15 Indications for Registration Intent Deep Pipeline Of 28 Unique Molecules With 14 First in Human Studies in Over 1,000 Patients to Date Los Angeles, CA, January 4, 2019 - NantCell and it’s founder Dr. Patrick Soon-Shiong announced today that Celgene has completed its crossover investment in NantCell.  Dr. Soon-Shiong will be introducing the company at the 37th Annual JP Morgan Healthcare Conference at the Westin St. Francis Hotel, San Francisco on Monday, January 7th at 8:30am. NantCell is a privately held immunotherapy company, whose goal is to employ a broad portfolio of biological molecules that will enable it to develop a cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy.  NantCell has one of the most comprehensive late stage clinical pipelines of an integrated platform of immunotherapy technologies addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4 and CD8 killer T cells). Currently the company is actively enrolling patients for registration trials in 15 indications. On December 19, 2018, Celgene completed a crossover funding round of $30 million in NantCell at a $4 billion valuation, bringing its overall investment in the company to $105 million with a 2.8% ownership in the company. This follows the May 2015 Celgene initial investment of $75 million in NantCell.  “We have partnered with Dr. Soon-Shiong and his mission to change the course of cancer from the very beginning,” said Mark Alles, Chairman and CEO of Celgene. “From his invention of Abraxane, to acquiring his company in 2010, to launching this protein nanoparticle drug as the backbone of immunotherapy to its current blockbuster status, and now to supporting his vision at NantCell of developing a chemo free cancer vaccine utilizing the body’s own immune system. Celgene invested in NantCell since its inception in 2015 and we are excited to extend this partnership today with the significant clinical progress he has made in developing cytokines and bispecific proteins in the ongoing quest to conquer this disease,” said Alles. Celgene announced on January 3, 2019 that it would be acquired by Bristol-Myers Squibb for $74 billion. “To our knowledge” said Soon-Shiong, “there is no other biotech or large pharma company with NantCell’s broad pipeline of bispecific and trispecific fusion cytokine proteins, peptides, mRNA, monoclonal antibodies, neoepitope and tumor associated vaccine delivery and cell therapy products, all in clinical phase of development, across multiple indications, for the treatment of cancer and infectious disease.  We are very pleased with Celgene’s continued investment in the company and our shared vision of developing a chemotherapy free cancer vaccine.” “With the clinical advances of the technology platforms across multiple tumor types at NantCell, the company is now poised to integrate the technologies developed at the two early stage immunotherapy public companies, NantHealth and NantKwest,” said Dr. Soon-Shiong, founder of all three companies.  “The adenovirus and yeast vector delivery systems in NantCell compliments the tumor associated antigen and neoepitope discovery engine (GPS CancerTM) developed by NantHealth, enabling the subcutaneous delivery of the neoepitopes to enable the recruitment  of T cells that target only expressed cancer mutations. The bispecific fusion cytokine proteins of NantCell stimulates the patient’s autologous primary NK and T cells, thereby supplementing the off-the-shelf, cryopreserved haNK cells developed by NantKwest.  Collectively the immunotherapy platforms in NantCell, NantHealth and NantKwest serve as a comprehensive path to the development of a cancer vaccine,” said Soon-Shiong. Der komplette Artikel auf: https://nantkwest.com/nantcell-announces-new-celgene-investment/

Microsoft hat vor ungefähr 2 Wochen die Zusammenarbeit mit ImmunityBio, welche auch zum Nantworks Konsortium gehören, gegen Covid-19 bekannt gegeben. Scheint doch eine größeres Ding zu werden.

Erstmal Strohfeuer. Jeder will beim Covid Thema mitmischen. Denke das Gleiche wie bei Sorrento, andere Firmen forschen schon länger daran und haben beim Umformen von bereits vorhanden Grippemedikamenten größere Erfolgschancen. Aber Sorrento verfolgt das gleiche Ziel mit einem ähnlichen Lösungsansatz, vielleicht ist ja was dran. Ist der Lösungsansatz mit Killerzellen erfolgreich, stehen natürlich Tür und Tor offen, weitere Krankheiten mit Killerzellen zu behandeln.

Wie schätzt ihr die News ein!?

Nasdaq hat noch nicht geöffnet und der Kurs hatte ohne Covid19 Behandlung schon das Hoch bei 9,90$... Schöner Tag!

https://finance.yahoo.com/news/nantkwest-immunitybio-announce-therapeutics-vaccines-123000368.html

News !!!! 🥳

@Lirum.. Ich habe beim meinen (Virtuellen) Broker knapp 3 Millionen Euro und kann damit Nantkwest komplett kaufen und dir ähnliche Screenshots zeigen.. Werde ich aber nicht tun ✋👍

Ich habe dir, Ad.ler, mal nen Screenshot von meinem S Broker Depot mit den Nantkwest Titeln reingestellt.

Stimmt. Kann er nicht 🙈

Warum bist du eigentlich in so vielen Foren am Tro.llen, man kann sich doch auch ganz normal mit dir unterhalten, hatte ich zumindest den Eindruck!?

Aha okay... Sofort geglaubt 🤣👍

Die Anderen hatte ich zu 2,66$ gekauft

Ja, für die 7000Stk, ich habe aber 21.000Stk.